U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT06963281) titled 'Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors' on April 30.
Brief Summary: The main purpose of this study is to evaluate the safety and tolerability of IBI3020 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RP2D) of IBI3020.
Study Start Date: April 29
Study Type: INTERVENTIONAL
Condition:
Solid Tumors
Intervention:
DRUG: IBI3020
Recombinant anti-CEACAM5 monoclonal antibody - dual-payload conjugate for injection
Recruitment Status: RECRUITING
Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Published by HT Digital Content Services with ...